Suven Life Sciences reports deeper losses as R&D spending surges

Suven Life Sciences Limited reported a consolidated net loss after tax of INR (7,730.99) lakhs for the quarter ended September 30, 2025, and INR (12,882.68) lakhs for the half-year. This compares to a net loss of INR (4,964.38) lakhs in the prior year's comparable quarter and INR (7,768.35) lakhs for the prior half-year period. Revenue from operations for the quarter stood at INR 91.92 lakhs.

Total consolidated expenses for the quarter increased to INR 8,200.71 lakhs, primarily driven by a significant rise in R&D expenses to INR 7,032.13 lakhs from INR 4,758.49 lakhs in the previous year's corresponding quarter. The company’s consolidated total comprehensive income for the quarter was INR (7,722.47) lakhs. Basic earnings per share (EPS) for the quarter were INR (3.48).

The company's board also approved the allotment of 9,186,490 equity shares on a preferential basis upon conversion of fully paid warrants, raising INR 12,309.90 lakhs. As of September 30, 2025, the total money received from the preferential issue was INR 30,673.43 lakhs, with INR 5,424.12 lakhs utilized and a balance of INR 25,249.31 lakhs remaining.